Neuropathy Outcome Assessment

Safety monitoring for glove compression includes adverse events such as blood flow impairment, pain, and allergic skin reactions during or after glove application. The primary outcome is the incidence of CTCAE grade 2 or higher chemotherapy-induced peripheral neuropathy of the hand, defined as onset in the fingers regardless of whether one or both hands are affected. FACT/GOG-Ntx-12 and EORTC QLQ-CIPN20 are patient-reported outcome measures selected to capture patients' subjective neuropathy experience and its effect on quality of life, complementing clinician-assessed CTCAE grading. The Debiopharm Neurologic and Sensory Toxicity Criteria (DEB-NTC) will evaluate persistence of OIPN symptoms and categorises severity by whether symptoms last less than or more than 7 days.